Cargando…

Prevention and management of adverse events related to regorafenib

Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in a range of solid tumors. Based on data from phase III clinical trials, regorafenib is indicated for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not co...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Wit, Mieke, Boers-Doets, Christine B., Saettini, Alessandra, Vermeersch, Kristina, de Juan, Carmen Roncero, Ouwerkerk, Jan, Raynard, See-See, Bazin, Ashley, Cremolini, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913844/ https://www.ncbi.nlm.nih.gov/pubmed/24337717 http://dx.doi.org/10.1007/s00520-013-2085-z

Ejemplares similares

Xerosis and pruritus as major EGFRI-associated adverse events
por: Clabbers, Julia M. K., et al.
Publicado: (2015)

Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib
por: Otsuka, Haruhiko, et al.
Publicado: (2022)

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
por: Yin, Xiaonan, et al.
Publicado: (2018)

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies
por: Chen, Dong-Yi, et al.
Publicado: (2022)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Trends of adverse events and mortality after DMARDs in patients with rheumatoid arthritis: Interrupted time‐series analysis
por: Fang, Yao‐Fan, et al.
Publicado: (2022)

Risk factors for major adverse kidney events in the first year after acute kidney injury
por: See, Emily J, et al.
Publicado: (2019)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

Correction: Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2019)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Adverse Events of DOACs in Children
por: Bosch, Alessandra, et al.
Publicado: (2022)

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
por: Grace, Elsie, et al.
Publicado: (2019)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Predicting Major Adverse Cardiovascular Events in Asian Type 2 Diabetes Patients With Lasso-Cox Regression
por: Rui Lam, Amanda Yun, et al.
Publicado: (2021)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
por: Chiesa, Silvia, et al.
Publicado: (2022)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g8tnkc44rtu2bmfkig9a4tonun